ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
41 announcements
Mangalam Drugs and Organics Ltd reported revenue from operations of ₹79.4 Cr (+61.1% YoY) and a net loss of ₹7.2 Cr for Q2 FY27.
Mangalam Drugs & Organics Ltd has dispatched physical letters to shareholders without registered emails. These letters provide web-links to access the Annual Report for FY 2025-26.
Mangalam Drugs and Organics appointed Prabhakar Raghunath Zavar as Non-Executive Independent Director for 60 months, effective 15 September 2026. The disclosure covers a board-level appointment with a background profile and no monetary amount.
Mangalam Drugs will hold a board meeting on 5 November 2026 to consider unaudited September 2026 quarter results. The agenda is proposed only, pending the meeting.
Mangalam Drugs issued a postal ballot notice seeking approval to re-appoint Praveen Saxena as independent director for a second five-year term. Voting closes 17 June 2026.
Mangalam Drugs and Organics Limited has reported a default amounting to Rs.1,557.27 Crore. The company has submitted a restructuring proposal to its banks to manage the obligation.
Mangalam Drugs and Organics Limited reported defaults on bank loan obligations totaling Rs. 15.57 Crore. The defaults involve cash credit accounts at Bank of Maharashtra and Bank of Baroda.
Mangalam Drugs and Organics Limited has issued a Postal Ballot notice to seek shareholder approval for appointing Shri Prabhakar Raghunath Zavar as an Independent Director. The appointment is for five years.
Mangalam Drugs and Organics Limited announced the appointment of new Statutory and Secretarial Auditors following the tenure completion of the previous Statutory Auditor.
Manglam Drugs and Organics Ltd. has appointed M/s S.N. Nanda & Co. as Statutory Auditor and M/s L.N. Joshi & Co. as Secretarial Auditor.
Mangalam Drugs and Organics Ltd held its 53rd Annual General Meeting on September 23, 2026. The meeting transacted standard business items including financial statement adoption and auditor appointments.
Mangalam Drugs and Organics reported a bank default amounting to Rs. 15.57 Crore. The company has submitted a restructuring proposal to the banks for resolution.
Mangalam Drugs disclosed a default on loan obligations to Bank of Maharashtra and Bank of Baroda, totaling ₹15.57 Crore in overdue amounts.
Mangalam Drugs and Organics Limited has appointed Mr. Prabhakar Raghunath Zavar as a Non-Executive Independent Director, effective September 15, 2026.
Mangalam Drugs & Organics appointed Mr. Prabhakar Raghunath Zavar as an Additional Independent Non-Executive Director for a five-year term at the latest board meeting.
Mangalam Drugs and Organics Limited scheduled its 53rd Annual General Meeting for September 23, 2026. The meeting will be held via video conferencing.
Mangalam Drugs disclosed defaults on loan obligations to Bank of Baroda and Bank of Maharashtra, totaling ₹15.57 Crore in overdue amounts.
Mangalam Drugs and Organics Ltd reported revenue from operations of ₹57.1 Cr (-0.2% YoY) and a net loss of ₹7.6 Cr for Q1 FY27.
Mangalam Drugs and Organics Limited announced the cessation of its Secretarial Auditor, M/s. Ragini Chokshi & Co., due to resignation effective August 4, 2026.
Mangalam Drugs and Organics Limited informed the exchanges that M/s. Ragini Chokshi & Co. has resigned as the company's Secretarial Auditor effective August 4, 2026.
Mangalam Drugs & Organics will hold a board meeting on August 12, 2026, to consider unaudited financial results and appoint auditors.
Mangalam Drugs and Organics reported a Rs. 15.57 Crore default on cash credit facilities. The defaults involve Bank of Baroda and Bank of Maharashtra accounts.
Mangalam Drugs reported a Rs.15.57 Crore bank default. The company has submitted a restructuring proposal to lenders to address the liability.
Mangalam Drugs and Organics reported a Rs 15.57 Crore default on cash credit facilities from two banks. The company is arranging funds to clear the overdue amounts.
Mangalam Worldwide submitted a security cover certificate for Rs. 50.19 Crore NCDs. The market value security cover ratio is 1.27.
Mangalam Worldwide Limited filed a Title Search Report confirming clear and marketable title for its industrial land in Sanand, Ahmedabad. This routine legal disclosure verifies ownership.
Mangalam Drugs and Organics filed its Annual Secretarial Compliance Report for FY2026. The report notes certain governance non-compliances regarding board and committee compositions.
Mangalam Drugs and Organics seeks shareholder approval via postal ballot for Shri Praveen Saxena's re-appointment. E-voting commences May 19, 2026, for a second five-year term.
Mangalam Drugs and Organics reported a ₹15.58 Crore bank default. The company has submitted a restructuring proposal to lenders to address the situation.
Mangalam Drugs and Organics Ltd reported revenue from operations of ₹67.3 Cr (-7.6% YoY) and a net loss of ₹13.4 Cr for Q4 FY26.